Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions

Avascular necrosis (AVN) of the hip is a debilitating condition predominantly affecting young adults, often leading to femoral head collapse and early joint replacement. Recent advances in regenerative medicine have highlighted the potential of bone marrow-derived stem cell therapy as a disease-modifying intervention. In this prospective study, 50 patients (mean age 38.5 years) with early to mid-stage AVN of the hip underwent autologous bone marrow-derived stem cell implantation. Patients were followed for 18 months, with clinical outcomes assessed using the Harris Hip Score (HHS), Visual Analog Scale (VAS) for pain, WOMAC, and SF-36 quality of life metrics. Subgroup analyses were performed by AVN stage. Significant improvements were observed across all clinical parameters. Mean HHS increased from 65.3 at baseline to 85.4 at 18 months (p<0.001), while mean VAS pain scores decreased from 7.8 to 2.8 (p<0.001). WOMAC scores improved from 65.2 to 30.2, and SF-36 domains showed an average 35% enhancement. Hip preservation was achieved in 90% of cases, with the greatest benefit seen in early-stage disease. No major complications or adverse events were reported. In conclusion, autologous bone marrow-derived stem cell therapy is a safe and effective treatment for early to mid-stage AVN of the hip, resulting in substantial pain relief, functional recovery, and improved quality of life. These findings support the integration of cellular therapy into standard AVN management protocols and underscore the need for further multicenter, long-term studies.